We are live on ! Find out more
BLFS icon

BioLife Solutions

80 hedge funds and large institutions have $168M invested in BioLife Solutions in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 42 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

163% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 16

0% more funds holding

Funds holding: 8080 (0)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

0.32% less ownership

Funds ownership: 50.36%50.04% (-0.32%)

2% less capital invested

Capital invested by funds: $170M → $168M (-$2.87M)

59% less call options, than puts

Call options by funds: $179K | Put options by funds: $437K

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
80
Holders Change
Holders Change %
0%
% of All Funds
1.58%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
10
Increased
42
Reduced
16
Closed
10
Calls
$179K
Puts
$437K
Net Calls
-$258K
Net Calls Change
+$183K
Name Holding Trade Value Shares
Change
Change in
Stake
Wells Fargo
26
Wells Fargo
California
$1.04M +$32.5K +1,996 +3%
New York State Common Retirement Fund
27
New York State Common Retirement Fund
New York
$991K
CCM
28
Cadence Capital Management
Massachusetts
$982K -$2.01M -123,603 -67%
IP
29
Isthmus Partners
Wisconsin
$864K +$598K +36,800 +222%
Bank of Montreal
30
Bank of Montreal
Ontario, Canada
$783K +$740K +45,540 +1,607%
QCMC
31
Quantum Capital Management (California)
California
$764K
Marshall Wace
32
Marshall Wace
United Kingdom
$752K +$756K +46,494 New
Goldman Sachs
33
Goldman Sachs
New York
$702K +$521K +32,031 +282%
Renaissance Technologies
34
Renaissance Technologies
New York
$490K +$243K +14,954 +98%
T. Rowe Price Associates
35
T. Rowe Price Associates
Maryland
$485K +$4.88K +300 +1%
CCA
36
Conestoga Capital Advisors
Pennsylvania
$482K +$251K +15,425 +107%
MFG
37
Magnus Financial Group
New York
$451K +$265K +16,308 +141%
PM
38
Penbrook Management
New York
$440K -$25.2K -1,550 -5%
Morgan Stanley
39
Morgan Stanley
New York
$434K +$192K +11,835 +79%
MFIM
40
Mesirow Financial Investment Management
Illinois
$412K -$13.6K -834 -3%
Franklin Resources
41
Franklin Resources
California
$398K +$400K +24,610 New
Charles Schwab
42
Charles Schwab
California
$298K +$22.8K +1,402 +8%
CS
43
Cannell & Spears
New York
$292K +$72.6K +4,467 +33%
JP Morgan Chase
44
JP Morgan Chase
New York
$286K +$252K +15,479 +700%
Janney Montgomery Scott
45
Janney Montgomery Scott
Pennsylvania
$285K +$44.7K +2,750 +18%
AA
46
Ancora Advisors
Ohio
$254K -$2.11K -130 -0.8%
Bank of America
47
Bank of America
North Carolina
$243K -$278K -17,086 -53%
SKK
48
Shepherd Kaplan Krochuk
Massachusetts
$227K
RG
49
Rathbones Group
United Kingdom
$226K -$8.94K -550 -4%
JG
50
Jefferies Group
New York
$211K +$212K +13,065 New

BLFS Hedge Fund Activity: Q4 2019 in Review

80 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q4 2019, worth a combined $168M — down 1.7% from $170M a quarter earlier.

Fund positioning in BLFS was balanced in Q4 2019: 10 funds opened new positions, 10 closed out, 42 added to existing stakes and 16 trimmed.

The largest buyer was Park West Asset Management, adding an estimated $1.32M. The largest seller was Fidelity Investments, exiting entirely with an estimated $2.49M sold.

  • 80 institutional investors held BioLife Solutions (BLFS) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $168M of BioLife Solutions stock for Q4 2019, down 1.7% quarter-over-quarter.
  • 10 funds opened new BioLife Solutions positions in Q4 2019 and 10 closed out, a net change of 0 holders.
  • The largest BioLife Solutions buyer in Q4 2019 was Park West Asset Management, an estimated $1.32M added.
  • The largest BioLife Solutions seller in Q4 2019 was Fidelity Investments, an estimated $2.49M sold.

Based on aggregated 13F filings for Q4 2019.